Erratum: Novel lipid-lowering therapies to reduce cardiovascular risk (JAMA (2021) 326:3 (266-267) DOI: 10.1001/jama.2021.2244)

J. T. Wilkins; D. M. Lloyd-Jones

doi:10.1001/jama.2021.14278

Erratum: Novel lipid-lowering therapies to reduce cardiovascular risk (JAMA (2021) 326:3 (266-267) DOI: 10.1001/jama.2021.2244)

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled "Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,"published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online.

Original language	English (US)
Pages (from-to)	873
Number of pages	1
Journal	JAMA - Journal of the American Medical Association
Volume	326
Issue number	9
DOIs	https://doi.org/10.1001/jama.2021.14278
State	Published - Sep 7 2021

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1001/jama.2021.14278

Cite this

@article{cdc44dafba1545ad8f8e5f3b905edf67,

title = "Erratum: Novel lipid-lowering therapies to reduce cardiovascular risk (JAMA (2021) 326:3 (266-267) DOI: 10.1001/jama.2021.2244)",

abstract = "Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled {"}Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,{"}published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online. ",

author = "Wilkins, {J. T.} and Lloyd-Jones, {D. M.}",

year = "2021",

month = sep,

day = "7",

doi = "10.1001/jama.2021.14278",

language = "English (US)",

volume = "326",

pages = "873",

journal = "JAMA - Journal of the American Medical Association",

issn = "0098-7484",

publisher = "American Medical Association",

number = "9",

}

TY - JOUR

T1 - Erratum

T2 - Novel lipid-lowering therapies to reduce cardiovascular risk (JAMA (2021) 326:3 (266-267) DOI: 10.1001/jama.2021.2244)

AU - Wilkins, J. T.

AU - Lloyd-Jones, D. M.

PY - 2021/9/7

Y1 - 2021/9/7

N2 - Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled "Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,"published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online.

AB - Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled "Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,"published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online.

UR - http://www.scopus.com/inward/record.url?scp=85113464441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113464441&partnerID=8YFLogxK

U2 - 10.1001/jama.2021.14278

DO - 10.1001/jama.2021.14278

M3 - Comment/debate

C2 - 34383011

AN - SCOPUS:85113464441

VL - 326

SP - 873

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0098-7484

IS - 9

ER -

Erratum: Novel lipid-lowering therapies to reduce cardiovascular risk (JAMA (2021) 326:3 (266-267) DOI: 10.1001/jama.2021.2244)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this